Stefano Gianotti Net Worth

The estimated Net Worth of Stefano Gianotti is at least $150 mil dollars as of 23 March 2018. Stefano Gianotti owns over 1,325 units of LivaNova PLC stock worth over $149,705 and over the last 8 years Stefano sold LIVN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Stefano Gianotti LIVN stock SEC Form 4 insiders trading

Stefano has made over 4 trades of the LivaNova PLC stock since 2016, according to the Form 4 filled with the SEC. Most recently Stefano exercised 1,325 units of LIVN stock worth $111,618 on 23 March 2018.

The largest trade Stefano's ever made was exercising 3,327 units of LivaNova PLC stock on 5 August 2017 worth over $157,866. On average, Stefano trades about 1,010 units every 92 days since 2016. As of 23 March 2018 Stefano still owns at least 3,155 units of LivaNova PLC stock.

You can see the complete history of Stefano Gianotti stock trades at the bottom of the page.

What's Stefano Gianotti's mailing address?

Stefano's mailing address filed with the SEC is 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON, X0, W2 1AY.

Insiders trading at LivaNova PLC

Over the last 9 years, insiders at LivaNova PLC have traded over $79,802,010 worth of LivaNova PLC stock and bought 4,000 units worth $268,530 . The most active insiders traders include William A Kozy, Two S.C.A.Tower 6 S. A R.L...., ePeter M Wilver. On average, LivaNova PLC executives and independent directors trade stock every 10 days with the average trade being worth of $315,922. The most recent stock trade was executed by Peter M Wilver on 15 June 2024, trading 2,680 units of LIVN stock currently worth $127,166.

What does LivaNova PLC do?

livanova plc is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.at livanova, we understand the importance of bringing both clinical and economic value to our customers. we are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. livanova is listed on the nasdaq stock exchange under the ticker symbol “livn.” livanova has approximately 3,000 employees worldwide. we are headquartered in london (uk) and maintain a presence in more than 100 countries. livanova is a worldwide leader in advanced circulatory support, cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.

Complete history of Stefano Gianotti stock trades at LivaNova PLC

LivaNova PLC executives and stock owners

LivaNova PLC executives and other stock owners filed with the SEC include:

• Damien McDonald,
  Chief Executive Officer, Director
• Keyna Skeffington,
  Senior Vice President, General Counsel and Company Secretary
• Alistair Simpson,
  Special Advisor
• Edward Andrle,
  Special Advisor
• Damien McDonald,
  CEO & Director
• Keyna Pidcock Skeffington,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Alex Shvartsburg,
  CFO and Corp. VP of Financial Planning, Analysis & International Region
• Daniel Moore,
  Independent Chairman of the Board
• Hugh Morrison,
  Independent Director
• Alfred Novak,
  Independent Director
• Francesco Bianchi,
  Independent Director
• Arthur Rosenthal,
  Independent Director
• Andrea Saia,
  Independent Director
• Sharon O'Kane,
  Independent Director
• William Kozy,
  Independent Director
• Stacy Seng,
  Independent Director
• Marco Dolci,
  Head of Global Operations and R&D
• Roy Khoury,
  President - International, Senior Vice President - Global Strategic Marketing
• Trui Hebbelinck,
  Chief Human Resource Officer
• Alex Shvartsburg,
  Interim Chief Financial Officer
• Stephanie Bolton,
  Pres of International Region
• Paul R. Buckman,
  Pres of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement
• Dr. Bryan D. Olin Ph.D.,
  Sr. VP & Head of Product Devel. - Neuromodulation
• Trui Hebbelinck,
  Chief HR Officer
• Matthew Joseph Dodds III,
  Sr. VP of Corp. Devel.
• Deanna Wilke,
  Director of Corp. Communications
• Lullo Stefano Di,
  Pres Cardiac Rhythm Mgmt
• Michel Darnaud,
  President Cardiac Surgery
• Thad Allen Huston,
  Chief Financial Officer
• Vivid Sehgal,
  CFO
• Two S.C.A.Tower 6 S. A R.L....,
  
• Jacques Gutedel,
  President Intercontinental
• Stefano Gianotti,
  Director
• Piero Vecchi,
  VP & Controller
• Pritpal Shinmar,
  SR VP Global Market Access
• Robert Jason Richey,
  President, Neuromodulation
• Douglas John Manko,
  Chief Accounting Officer
• David S Wise,
  SR VP HR & IT
• Todd C Schermerhorn,
  Director
• Ahmet Tezel,
  Chief Innovation Officer
• Brian Sheridan,
  SR VP Genl Counsel & Secretary
• Andre Michel Ballester,
  CEO
• Demetrio Mauro,
  Chief Integration Officer
• James Christopher Barry,
  Director
• Peter M Wilver,
  Director
• Brooke Story,
  Director
• Michael Damon Hutchinson,
  Chief Legal Officer
• Stephanie Bolton,
  President, Global Epilepsy
• Vladimir Makatsaria,
  Chief Executive Officer